JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

ADMA Biologics Inc

Chiusa

SettoreSettore sanitario

19 -4.38

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

18.93

Massimo

19.86

Metriche Chiave

By Trading Economics

Entrata

-85M

27M

Vendite

-2.7M

115M

P/E

Media del settore

22.571

34.393

Margine di Profitto

23.435

Dipendenti

685

EBITDA

-4.7M

35M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+68.26% upside

Dividendi

By Dow Jones

Utili prossimi

6 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

725M

4.5B

Apertura precedente

23.38

Chiusura precedente

19

Notizie sul Sentiment di mercato

By Acuity

50%

50%

176 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

ADMA Biologics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

28 apr 2025, 14:13 UTC

I principali Market Mover

ADMA Biologics Shares Hit 52-Week High After FDA Approval

Confronto tra pari

Modifica del prezzo

ADMA Biologics Inc Previsione

Obiettivo di Prezzo

By TipRanks

68.26% in crescita

Previsioni per 12 mesi

Media 33.5 USD  68.26%

Alto 35 USD

Basso 32 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per ADMA Biologics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

2

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

N/A / 23.5406Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Weak Bullish Evidence

Sentiment

By Acuity

176 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.